Search results
Found 1831 matches for
Participants in South Africa’s first clinical trial for a vaccine against COVID-19 are to be vaccinated this week.
Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study
COVID-19
16 May 2022
COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.
Oral paratyphoid vaccine to begin human trials
10 May 2022
The University of Oxford in collaboration with the University of Maryland School of Medicine (UMSoM) has begun recruiting for a Phase I/II trial of a new paratyphoid vaccine in human volunteers in Oxford.
Oxford to work with Brazil to establish clinical research hub
COVID-19 Research
8 November 2021
The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.
Professor Sue Ann Costa Clemens awarded an Honorary CBE
Awards & Appointments
24 September 2021
Congratulations to Professor Sue Ann Costa Clemens for her Honarary CBE award for her positive contribution towards public health. Here at the Oxford Vaccine Group and the Paediatrics department, we are extremely proud of what Sue and her team have achieved.
We shouldn’t be giving Covid boosters while millions wait for a first dose
20 August 2021
There’s no evidence yet that top-up shots are needed, so let’s help those around the world who urgently need the vaccine - writes Andrew Pollard in an opinion piece for The Guardian.
University of Oxford researchers among recipients of Ireland and UK joint research awards for digital humanities in €6.5m boost for interdisciplinary research partnerships
Awards & Appointments
9 August 2021
Dr Samantha Vanderslott (Oxford Vaccine Group) and Dr Claas Kirchhelle (University College Dublin) have had their three-year project ‘Typhoid, Cockles, and Terrorism’ about the history of typhoid in Dublin successfully funded.
One billion doses: A moment to celebrate but not a time to be complacent
COVID-19
30 July 2021
Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group and Professor of Paediatric Infection and Immunity, takes a moment to reflect on one billion doses of the Oxford coronavirus vaccine released worldwide.
Severe disease, not mild infection, makes a pandemic – vaccines still offer our best hope
COVID-19
30 July 2021
If the current high levels of protection against severe disease are sustained, the global public health emergency will be curtailed by the ongoing vaccine rollout - writes Andrew Pollard for The Independent.
Oxford vaccine reaches one billion doses released
COVID-19
29 July 2021
The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.
Phase I trial begins of new vaccine against the Plague
Research
27 July 2021
Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.
Oxford Vaccine Group among winners at NHS Parliamentary awards
Awards & Appointments COVID-19
9 July 2021
Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.
New book highlights life-saving role vaccines play in prevention of killer diseases
Publication
9 July 2021
'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.
Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study
COVID-19
30 June 2021
Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.
Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response
COVID-19 Research
28 June 2021
Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.
First trial participants vaccinated with Oxford COVID-19 variant vaccine
COVID-19
28 June 2021
The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.
Oxford researchers identify levels of antibody protection required to prevent symptomatic COVID-19
COVID-19
28 June 2021
Researchers from the University of Oxford have today released their findings about the so-called ‘correlates of protection’ against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.
Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study
COVID-19 Publication
21 June 2021
A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.
How do childhood vaccination policies vary across the world?
Publication
17 June 2021
Read about the topic in Samantha Vanderslott's latest publication.
OVG's director recognised in Queen’s Birthday Honours
Awards & Appointments
11 June 2021
Andrew Pollard, Director of the Oxford Vaccine Group, and Professor of Paediatric Infection and Immunity, becomes a Knight Bachelor for services to Public Health, particularly during the COVID-19 Pandemic.
COVID-19 vaccine messaging that focuses on personal benefits is most effective with those who are hesitant
COVID-19 Public Engagement
14 May 2021
For the one in ten who say they won’t take a COVID-19 vaccine, messaging that focuses on personal rather than collective benefits is more effective.